Biocon Biologics Partner Viatris Wins U.S. Court Decisions on Sanofi Appeals for Lantus® Device Patents

Biocon Biologics Ltd., a subsidiary of Biocon Ltd. (BSE code: 532523, NSE: BIOCON), today announced that the U.S. Court of Appeals for the Federal Circuit (USCAFC) has upheld the U.S. Patent and Trademark Appeal Board's decisions for unpatentability of five device patents for Sanofi's Lantus® SoloSTAR®, as well as a district court decision on one of these patents. The Patent Trial and Appellate Board (PTAB) at the U.S. Patent and Trademark Office (USPTO) had in April and May 2020 found the challenged claims of U.S. Patent Nos. 8,679,069; 8,603,044; 8,992,486; 9,526,844; 9,604,008 unpatentable. Sanofi had appealed against all these PTAB decisions to USCAFC.

Of these five patents, the 9,526,844 ("the '844 Patent") was also held invalid and "not infringed" by the U.S. District Court for the District of New Jersey. The district court found non-infringement of the asserted claims for the '844 patent and held it invalid for lack of written description. Sanofi had appealed the district court decision for the '844 patent. Since the USCAFC affirmed PTAB's decision for the '844 patent, Sanofi's appeal against the district court's decision is held as moot and thus dismissed. The Federal Circuit judgments reinforce the continuing efforts of Biocon Biologics and Viatris to break down barriers to patient access for important medicines such as Semglee®. Viatris and Biocon Biologics Ltd. launched their interchangeable Semglee® products (insulin glargine-yfgn) last month, which are the first, and currently the only, interchangeable biosimilars to Lantus®, providing more affordable options for the millions of Americans living with diabetes.

The Semglee® products are available in vial and prefilled pen presentations and are interchangeable for the reference brand, Lantus®, allowing for substitution at the pharmacy counter. Semglee® is indicated to help control high blood sugar in adult and pediatric patients with type 1 diabetes and adults with type 2 diabetes.

Shreehas Tambe, dCEO, Biocon Biologics, said: "The decision of the U.S. federal court in favour of our partner Viatris, on all the five Sanofi Lantus® SoloSTAR® device patents is a vindication of our long-held position on intellectual property. These developments are very encouraging and will greatly help in breaking down barriers to patient access. With Semglee®, we will be able to offer people living with diabetes in the U.S. more treatment options, rationalize cost of therapy and generate savings for the overall healthcare system."

Lantus is a long-acting insulin used to treat adults with type 2 diabetes and adults and pediatric patients with type 1 diabetes for the control of high blood sugar. Sanofi sells the product in vials (Lantus®) and as a disposable injection pen (Lantus SoloSTAR®).

Sanofi's total sales in the U.S. as per IQVIA for the 12 months ending September 30, 2021, were ~USD 1.4 billion for Lantus® 100 Units/mL vial and ~USD 5.1 billion for Lantus® SoloSTAR® 100 Units/mL.

Shares of Biocon Limited was last trading in BSE at Rs. 361.15 as compared to the previous close of Rs. 361.50. The total number of shares traded during the day was 131414 in over 2615 trades.

The stock hit an intraday high of Rs. 367.40 and intraday low of 359.15. The net turnover during the day was Rs. 47722278.00.

Source : Equity Bulls

Keywords

Biocon INE376G01013 BioconBiologics USCAFC Viatris